Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

Non-small cell lung cancer (NSCLC) is one of the leading causes of death worldwide, with the majority of patients diagnosed in advanced stages of the disease, when treatment is only palliative. While the standard of care is chemotherapy for these patients, the emergence of new treatments aimed at target molecules has been a breakthrough. Patients with somatic mutations in the EGFR gene respond to treatment with tyrosine kinase inhibitors (TKIs), while those with alterations in ALK, RET or ROS1 genes could benefit from treatment with crizotinib.

2p23, ALK 7q34, BRAF EGFR 6q22, ROS1